Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical textbooks present as relatively binary: remove the entire prostate gland or irradiate it, accept the significant functional consequences, and get on with the business of surviving. Surgery that removes the whole gland or whole-gland radiation therapy has long carried a heavy price: incontinence, erectile dysfunction, bowel complications, and weeks to months of recovery that reshape a man’s sense of himself. For decades, the medical calculus went something like this: trade a significant piece of your quality of life now to preserve your life later. For hundreds of thousands of men each year, that was the deal on the table, and most took it because there was nothing better.
That calculus is now being seriously challenged. A body of clinical evidence, gaining both volume and confidence, points to a different possibility – one where doctors treat only the cancerous section of the prostate, leaving healthy surrounding tissue intact, with outcomes for cancer control that rival whole-gland treatment and side effects that are dramatically reduced. The approach is called focal therapy, and it has moved from the fringes of urology into a genuine, fiercely debated conversation about what the future standard of care for localized prostate cancer should look like.
The stakes of this conversation are not abstract. In 2026, an estimated 333,830 new cases of prostate cancer will be diagnosed in the United States, with an estimated 36,320 deaths from the disease. Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly. The five-year relative survival rate for distant-stage prostate cancer is only 38%, but approaches 100% for earlier-stage diagnoses – which means that what happens at the moment of localized detection, the treatment decisions made in those early clinical conversations, carries enormous weight. Focal therapy plants itself precisely in that moment.
What Focal Therapy Actually Is
Traditional whole-gland treatments – radical prostatectomy (surgical removal of the entire prostate) and external beam radiation – proceed from the assumption that the whole gland must be addressed. Radical therapy with surgery or radiation has been the gold standard for treatment of localized prostate cancer, but it is associated with significant treatment-related sexual, urinary, and bowel morbidity.
Focal therapy rejects that premise. Focal therapy targets only the area of cancer within the prostate for destruction, potentially sparing the adjacent critical anatomical structures responsible for sexual, urinary, and bowel function from damage, and thus preserving quality of life. The approach is grounded in what researchers call the Index Lesion Theory: the understanding that disease progression in prostate cancer is primarily driven by the most aggressive lesion within the gland, not by smaller, lower-grade satellite foci distributed elsewhere. By targeting and destroying that index lesion precisely, clinicians aim to stop progression while leaving the nerves and muscle structures around the prostate untouched.
The tools used to accomplish this have evolved considerably. Current ablative modalities include high-intensity focused ultrasound (HIFU), cryoablation, focal laser, irreversible electroporation (IRE), and photodynamic therapy (PDT), which are FDA-approved for the treatment of prostate tissue. Of these, HIFU has become the most widely studied and practiced modality in focal therapy to date. High-intensity focused ultrasound uses intense ultrasound energy waves to heat cancerous prostate tissue and destroy cancer cells. Ultrasound waves are concentrated into a small focal point within the prostate and temperature is increased to over 190°F almost instantly. The precision is the point: the treatment ablates cancer millimeter by millimeter, guided by real-time imaging, while leaving the surrounding tissue unharmed.
What the Evidence Shows
The clinical data on focal therapy has been accumulating for nearly two decades, and the picture it draws is genuinely encouraging – with honest caveats attached.
The largest dataset to date comes from the HEAT (HIFU Evaluation and Assessment of Treatment) registry, which tracked 1,379 patients treated across 13 centers over a 15-year period. Kaplan-Meier seven-year failure-free survival was 69%, with seven-year failure-free survival in intermediate- and high-risk cancers at 68% and 65% respectively. Serious adverse events occurred in only 0.5% of patients. Critically, metastasis-free survival and prostate cancer-specific mortality at seven years were both 100%, and overall survival at seven years was 97%.
A pivotal multi-center prospective study involving 625 patients, published in European Urology, found similarly striking results at five years. Failure-free survival, metastasis-free survival, cancer-specific survival, and overall survival were 88%, 98%, 100%, and 99%, respectively. Urinary incontinence, one of the most feared consequences of traditional prostate surgery, affected just 2% of patients.
The most comprehensive synthesis of prospective data to date arrived in 2025. A systematic review and meta-analysis published in European Urology Oncology analyzed 50 studies encompassing 4,615 patients treated with focal therapies, finding estimates of 12- and 24-month clinically significant cancer recurrence-free survival rates of 86% and 81%, respectively. Those are short-to-medium term findings – the authors were careful to note the limitations of follow-up duration – but they represent the most rigorous aggregation of prospective evidence yet produced, and they point in a consistent direction.
A phase 2 clinical trial at Memorial Sloan Kettering Cancer Center provided some of the most clinically striking quality-of-life data. In a trial of 101 men who received HIFU treatment and were biopsied at six and 24 months, nearly 90% had no intermediate- or higher-risk cancer remaining in the treated area. Nobody in the study reported urinary incontinence or experienced bowel problems, and most men were able to achieve erections. Based on this data, the FDA granted approval for the technology to treat prostate tissue. The urologist leading the trial, Dr. Behfar Ehdaie, described it as treating specific areas of the prostate rather than removing all the tissue – an approach he characterized as “much easier for patients.”
The Role of Advanced Imaging
Focal therapy does not operate in a vacuum. Its precision depends entirely on the precision of what precedes it: diagnosis. The emergence of multiparametric MRI (mpMRI) and PSMA PET imaging as standard diagnostic tools has been the critical development that made focal therapy more viable, because you cannot treat what you cannot clearly locate.
The widespread adoption of multiparametric magnetic resonance imaging in most urology departments, together with the development of fusion biopsy techniques, has led to a growing number of early-stage prostate cancer diagnoses – often at less aggressive stages. Advanced imaging techniques, especially mpMRI and PSMA-PET/CT, play a central role in accurately localizing the index lesion, and in combination with targeted biopsy strategies, particularly fusion image-guided biopsy, these tools enhance diagnostic precision and facilitate the identification of candidates most likely to benefit from focal therapy.
Artificial intelligence is beginning to refine this further. Researchers at UCLA Health have developed an AI tool called Unfold AI that combines MRI data with biopsy results to generate a detailed three-dimensional map of where cancer sits inside the prostate. A study published in the Journal of Urology showed that the AI system defined the boundaries of cancerous tissue far more accurately than conventional methods, making predictions of tumor size 45 times more precise than doctors’ assessments alone. Greater imaging precision directly improves treatment targeting – and in focal therapy, targeting is everything.
Patient Selection: Not Every Case Qualifies
The enthusiasm around focal therapy comes with a critical caveat that every fair-minded clinician raises: this approach is not appropriate for all patients. The outcomes data above is drawn from carefully selected patient populations, and the clinical community is emphatic that generalization beyond those populations would be premature and potentially harmful.
When considering who is the right patient for focal therapy, intermediate-risk patients appear to be the “sweet spot.” These patients typically have a longer lead time to metastatic disease, a lower risk of mortality, and if focal therapy fails, salvage treatment remains feasible within a five- to ten-year window, with disease likely to remain localized. Moreover, many of these patients would otherwise go on to require radical therapy if managed with surveillance alone.
Patient selection is the most important factor in ensuring good outcomes following focal therapy. Ideally, the approach should be reserved for men with unifocal or unilateral disease – attempting to use focal therapy in men with multifocal disease could lead to suboptimal results, both in terms of cancer control and functional preservation.
The use of focal therapy in men with high-risk disease remains more controversial, given concerns about metastatic progression, the possibility of occult metastases at baseline, and a higher risk of local failure. Young men may also not be ideal candidates, as the long-term durability of focal therapy remains unproven, and salvage prostatectomy after focal therapy may lead to reduced functional outcomes. The international FALCON consensus project, which brought together experts to define optimal patient selection criteria, concluded that candidates should have an MRI-visible lesion and intermediate-grade (ISUP Grade 2) disease as a baseline threshold.
Where Leading Medical Authorities Stand
The evolving medical consensus reflects the tension between promising evidence and the absence of long-term randomized controlled trials directly comparing focal therapy against radical treatment.
The American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO), in their 2026 joint guideline update, inform patients with low- and intermediate-risk prostate cancer that whole-gland or focal ablation remains investigational without high-quality data comparing ablation outcomes to standard-of-care therapies such as surgery, radiation therapy, and active surveillance. This is a measured position, not a dismissal – the guidelines distinguish between “investigational” and “ineffective,” and the European Association of Urology similarly recommends that focal therapy be offered within clinical trials or registries, a position designed to accelerate the generation of long-term comparative data rather than shut the door on the approach.
At the 2025 American Urological Association annual meeting, Dr. Samir Taneja, Professor of Urologic Oncology at NYU Grossman School of Medicine and one of the field’s foremost experts, delivered a featured lecture on the question of whether focal therapy was ready for mainstream clinical use. He concluded that focal therapy has demonstrated favorable locoregional disease control for up to five to ten years, with reproducible outcomes that appear independent of energy source or disease risk and a low rate of metastatic progression. Advances in diagnostic and staging tools have further empowered more precise candidate selection and follow-up strategies. However, long-term comparative outcomes and definitive evidence of mortality benefit are still lacking.
His answer to whether focal therapy is ready for prime time was conditional but affirmative: it is ready, but only if it is done well, with careful candidate selection, meticulous treatment planning, complete and aggressive treatment of the index tumor, rigorous follow-up, and early salvage of any recurrence.
At the same meeting, a crossfire debate session on focal therapy for intermediate-risk disease produced a summary that captured where the clinical frontier now sits: focal therapy represents a natural evolution in surgical oncology, building on the precision diagnosis advances of the past decade. Treatment-related side effects are reduced five- to ten-fold compared to radical therapy. Focal therapy has shown iso-effective cancer control compared to radical therapy at five to ten years, and should be routinely offered as a standard option for eligible intermediate-risk patients, with select high-risk cases also considered appropriate candidates. That represents a meaningful shift in clinical posture from where the field stood even three years ago.
The Outstanding Questions
The honest account of focal therapy’s promise requires equal time spent on what is still unknown. The absence of large, long-term, randomized controlled trials is the most significant gap in the evidence base. The existing data – even the impressive multi-center registry studies – are not randomized. Patients who receive focal therapy are often selected because they are good candidates for it, and good candidates tend to do well. Disentangling the effect of treatment from the effect of favorable tumor biology is genuinely difficult.
Focal therapy is a highly specialized procedure that requires a high level of expertise. Surgeons performing HIFU need to be skilled in advanced imaging techniques to accurately locate and target the cancerous tissue, and centers offering focal therapy must have not only the right technology but also the experience and procedural volume to ensure optimal outcomes. The concentration of expertise at major academic centers means that outcomes achieved in registry studies may not be replicable everywhere as adoption broadens.
Recurrence management also requires careful attention. The therapeutic goal of focal therapy is distinct from that of conventional treatments: while there is a high likelihood of residual cancer foci of uncertain significance, the primary goal is the prevention of metastasis and cancer-related mortality. Focal therapy should be considered a disease management strategy rather than a curative one. Re-treatment must be seen as both acceptable and feasible, integrated as part of the overall management plan. That framing matters enormously for patients weighing their options: focal therapy is not, for most patients, a single treatment and done. It is an ongoing monitoring relationship with their cancer.
Read More: These Signs of Aging After 40 Look Normal But Could Mean Health Issues
What This Means Right Now
Focal therapy for prostate cancer has moved from a fringe idea to a credible clinical option with a growing evidence base, meaningful institutional backing, and serious consideration for routine use in eligible intermediate-risk patients. The data at five to ten years is genuinely encouraging on both cancer control and quality of life. The absence of randomized controlled trial data comparing it directly to surgery or radiation remains the most significant unanswered question, and it is one the field acknowledges openly.
For patients and the families who accompany them through a diagnosis, the immediate practical implication is that the conversation with a urologist following a prostate cancer diagnosis is now more complex – but also more promising – than it was a decade ago. Focal therapy is not right for everyone. The guidelines are clear on that, and so is the evidence. But for men with localized, intermediate-risk, MRI-visible disease at a center with genuine expertise in the approach, focal therapy represents a real choice where none meaningfully existed before.
Whether it becomes the standard of care will depend on the comparative trial data that is now actively being generated. What the evidence already supports is that it belongs in the conversation – with honesty about what it can and cannot yet guarantee. For men sitting in an oncologist’s office trying to decide between options that all carry costs, that is not a small thing.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.